The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: Outcomes in patients receiving monotherapy

Stevo Julius, Michael A. Weber, Sverre E. Kjeldsen, Gordon T. McInnes, Alberto Zanchetti, Hans R. Brunner, John Laragh, M. Anthony Schork, Tsushung A. Hua, John Amerena, Ivan Balazovjech, Graham Cassel, Bela Herczeg, Nevres Koylan, Dieter Magometschnigg, Silja Majahalme, Felipe Martinez, Willie Oigman, Ricardo Seabra Gomes, Jun Ren Zhu

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan- or amlodipine-based regimens. In this report, we analyzed outcomes in 7080 patients (46.4%) who, at the end of the initial drug adjustment period (6 months), remained on monotherapy. Baseline characteristics were similar in the valsartan (N=3263) and amlodipine (N=3817) groups. Time on monotherapy was 3.2 years (78% of treatment exposure time). The average in-trial blood pressure was similar in both groups. Event rates in the monotherapy group were 16% to 39% lower than in the main VALUE trial. In the first analysis, we censored patients when they discontinued monotherapy ("censored"); in the second, we counted events regardless of subsequent therapy (intention-to-treat principle). We also assessed the impact of duration of monotherapy on outcomes. No difference was found in primary composite cardiac end points, strokes, myocardial infarctions, and all-cause deaths with both analyses. Heart failure in the valsartan group was lower both in the censored and intention-to-treat analyses (hazard ratios: 0.63, P=0.004 and 0.78, P=0.045, respectively). Longer duration of monotherapy amplified between-group differences in heart failure. New-onset diabetes was lower in the valsartan group with both analyses (odds ratios: 0.78, P=0.012 and 0.82, P=0.034). Thus, despite lower absolute event rates in monotherapy patients, the relative risks of heart failure and new-onset diabetes favored valsartan. Moreover, these findings support the feasibility of comparative prospective trials in lower-risk hypertensive patients.

Original languageEnglish
Pages (from-to)385-391
Number of pages7
JournalHypertension
Volume48
Issue number3
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Valsartan
Antihypertensive Agents
Heart Failure
Social Adjustment
Amlodipine
Intention to Treat Analysis
Cause of Death
Stroke
Odds Ratio
Myocardial Infarction
Blood Pressure

Keywords

  • Clinical trials
  • Diabetes mellitus
  • Heart failure

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Julius, S., Weber, M. A., Kjeldsen, S. E., McInnes, G. T., Zanchetti, A., Brunner, H. R., ... Zhu, J. R. (2006). The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: Outcomes in patients receiving monotherapy. Hypertension, 48(3), 385-391. https://doi.org/10.1161/01.HYP.0000236119.96301.f2

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial : Outcomes in patients receiving monotherapy. / Julius, Stevo; Weber, Michael A.; Kjeldsen, Sverre E.; McInnes, Gordon T.; Zanchetti, Alberto; Brunner, Hans R.; Laragh, John; Schork, M. Anthony; Hua, Tsushung A.; Amerena, John; Balazovjech, Ivan; Cassel, Graham; Herczeg, Bela; Koylan, Nevres; Magometschnigg, Dieter; Majahalme, Silja; Martinez, Felipe; Oigman, Willie; Gomes, Ricardo Seabra; Zhu, Jun Ren.

In: Hypertension, Vol. 48, No. 3, 09.2006, p. 385-391.

Research output: Contribution to journalArticle

Julius, S, Weber, MA, Kjeldsen, SE, McInnes, GT, Zanchetti, A, Brunner, HR, Laragh, J, Schork, MA, Hua, TA, Amerena, J, Balazovjech, I, Cassel, G, Herczeg, B, Koylan, N, Magometschnigg, D, Majahalme, S, Martinez, F, Oigman, W, Gomes, RS & Zhu, JR 2006, 'The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: Outcomes in patients receiving monotherapy', Hypertension, vol. 48, no. 3, pp. 385-391. https://doi.org/10.1161/01.HYP.0000236119.96301.f2
Julius, Stevo ; Weber, Michael A. ; Kjeldsen, Sverre E. ; McInnes, Gordon T. ; Zanchetti, Alberto ; Brunner, Hans R. ; Laragh, John ; Schork, M. Anthony ; Hua, Tsushung A. ; Amerena, John ; Balazovjech, Ivan ; Cassel, Graham ; Herczeg, Bela ; Koylan, Nevres ; Magometschnigg, Dieter ; Majahalme, Silja ; Martinez, Felipe ; Oigman, Willie ; Gomes, Ricardo Seabra ; Zhu, Jun Ren. / The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial : Outcomes in patients receiving monotherapy. In: Hypertension. 2006 ; Vol. 48, No. 3. pp. 385-391.
@article{610787d5a11c4c47a4556c0bf71a1e50,
title = "The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: Outcomes in patients receiving monotherapy",
abstract = "In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan- or amlodipine-based regimens. In this report, we analyzed outcomes in 7080 patients (46.4{\%}) who, at the end of the initial drug adjustment period (6 months), remained on monotherapy. Baseline characteristics were similar in the valsartan (N=3263) and amlodipine (N=3817) groups. Time on monotherapy was 3.2 years (78{\%} of treatment exposure time). The average in-trial blood pressure was similar in both groups. Event rates in the monotherapy group were 16{\%} to 39{\%} lower than in the main VALUE trial. In the first analysis, we censored patients when they discontinued monotherapy ({"}censored{"}); in the second, we counted events regardless of subsequent therapy (intention-to-treat principle). We also assessed the impact of duration of monotherapy on outcomes. No difference was found in primary composite cardiac end points, strokes, myocardial infarctions, and all-cause deaths with both analyses. Heart failure in the valsartan group was lower both in the censored and intention-to-treat analyses (hazard ratios: 0.63, P=0.004 and 0.78, P=0.045, respectively). Longer duration of monotherapy amplified between-group differences in heart failure. New-onset diabetes was lower in the valsartan group with both analyses (odds ratios: 0.78, P=0.012 and 0.82, P=0.034). Thus, despite lower absolute event rates in monotherapy patients, the relative risks of heart failure and new-onset diabetes favored valsartan. Moreover, these findings support the feasibility of comparative prospective trials in lower-risk hypertensive patients.",
keywords = "Clinical trials, Diabetes mellitus, Heart failure",
author = "Stevo Julius and Weber, {Michael A.} and Kjeldsen, {Sverre E.} and McInnes, {Gordon T.} and Alberto Zanchetti and Brunner, {Hans R.} and John Laragh and Schork, {M. Anthony} and Hua, {Tsushung A.} and John Amerena and Ivan Balazovjech and Graham Cassel and Bela Herczeg and Nevres Koylan and Dieter Magometschnigg and Silja Majahalme and Felipe Martinez and Willie Oigman and Gomes, {Ricardo Seabra} and Zhu, {Jun Ren}",
year = "2006",
month = "9",
doi = "10.1161/01.HYP.0000236119.96301.f2",
language = "English",
volume = "48",
pages = "385--391",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial

T2 - Outcomes in patients receiving monotherapy

AU - Julius, Stevo

AU - Weber, Michael A.

AU - Kjeldsen, Sverre E.

AU - McInnes, Gordon T.

AU - Zanchetti, Alberto

AU - Brunner, Hans R.

AU - Laragh, John

AU - Schork, M. Anthony

AU - Hua, Tsushung A.

AU - Amerena, John

AU - Balazovjech, Ivan

AU - Cassel, Graham

AU - Herczeg, Bela

AU - Koylan, Nevres

AU - Magometschnigg, Dieter

AU - Majahalme, Silja

AU - Martinez, Felipe

AU - Oigman, Willie

AU - Gomes, Ricardo Seabra

AU - Zhu, Jun Ren

PY - 2006/9

Y1 - 2006/9

N2 - In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan- or amlodipine-based regimens. In this report, we analyzed outcomes in 7080 patients (46.4%) who, at the end of the initial drug adjustment period (6 months), remained on monotherapy. Baseline characteristics were similar in the valsartan (N=3263) and amlodipine (N=3817) groups. Time on monotherapy was 3.2 years (78% of treatment exposure time). The average in-trial blood pressure was similar in both groups. Event rates in the monotherapy group were 16% to 39% lower than in the main VALUE trial. In the first analysis, we censored patients when they discontinued monotherapy ("censored"); in the second, we counted events regardless of subsequent therapy (intention-to-treat principle). We also assessed the impact of duration of monotherapy on outcomes. No difference was found in primary composite cardiac end points, strokes, myocardial infarctions, and all-cause deaths with both analyses. Heart failure in the valsartan group was lower both in the censored and intention-to-treat analyses (hazard ratios: 0.63, P=0.004 and 0.78, P=0.045, respectively). Longer duration of monotherapy amplified between-group differences in heart failure. New-onset diabetes was lower in the valsartan group with both analyses (odds ratios: 0.78, P=0.012 and 0.82, P=0.034). Thus, despite lower absolute event rates in monotherapy patients, the relative risks of heart failure and new-onset diabetes favored valsartan. Moreover, these findings support the feasibility of comparative prospective trials in lower-risk hypertensive patients.

AB - In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan- or amlodipine-based regimens. In this report, we analyzed outcomes in 7080 patients (46.4%) who, at the end of the initial drug adjustment period (6 months), remained on monotherapy. Baseline characteristics were similar in the valsartan (N=3263) and amlodipine (N=3817) groups. Time on monotherapy was 3.2 years (78% of treatment exposure time). The average in-trial blood pressure was similar in both groups. Event rates in the monotherapy group were 16% to 39% lower than in the main VALUE trial. In the first analysis, we censored patients when they discontinued monotherapy ("censored"); in the second, we counted events regardless of subsequent therapy (intention-to-treat principle). We also assessed the impact of duration of monotherapy on outcomes. No difference was found in primary composite cardiac end points, strokes, myocardial infarctions, and all-cause deaths with both analyses. Heart failure in the valsartan group was lower both in the censored and intention-to-treat analyses (hazard ratios: 0.63, P=0.004 and 0.78, P=0.045, respectively). Longer duration of monotherapy amplified between-group differences in heart failure. New-onset diabetes was lower in the valsartan group with both analyses (odds ratios: 0.78, P=0.012 and 0.82, P=0.034). Thus, despite lower absolute event rates in monotherapy patients, the relative risks of heart failure and new-onset diabetes favored valsartan. Moreover, these findings support the feasibility of comparative prospective trials in lower-risk hypertensive patients.

KW - Clinical trials

KW - Diabetes mellitus

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=33747434821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747434821&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.0000236119.96301.f2

DO - 10.1161/01.HYP.0000236119.96301.f2

M3 - Article

C2 - 16864741

AN - SCOPUS:33747434821

VL - 48

SP - 385

EP - 391

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 3

ER -